Lv2
150 积分 2025-11-23 加入
P3.13.34 Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307
3天前
求助中
Minimal residual disease as a target for liquid biopsy in patients with solid tumors
6天前
已完结
Adjuvant therapy-free strategy for stage IB to IIIA non-small-cell lung cancer patients after radical resection based on longitudinal undetectable molecular residual disease: prospective, multicenter, single-arm study
8天前
已完结
A meta-analysis of circulating tumor DNA as a survival indicator in small cell lung cancer patients
20天前
已完结
Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
21天前
已完结
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer
25天前
已完结
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer
30天前
已完结
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
1个月前
已完结
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer
1个月前
已完结
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
1个月前
已完结
皖公网安备34019202002308
